first of my name, father of unicorns, bane of cancer cells, lord of lightning, maker of healing devices and teacher of design. Assoc Prof at UMass Amherst.
@JuliusChapiro Most medical components are built on top of standard/industrial gas/liquid handling ones. McMaster or similar may have tubing that you can repurpose “off label”
Courageous and great article from @MSKCancerCenter on Histotripsy published in @cvironco ! Link: https://t.co/ubMPOeRioK
“Patients arrive with predetermined expectations shaped by marketing rather than clinical reality, pressuring physicians
to offer treatments lacking comprehensive validation. Healthcare institutions acquire expensive systems to
remain competitive, even when clinical need may not justify the investment. Resources are diverted toward technologies with limited proven benefit, while established treatments receive diminished attention.”
“Aggressive promotion, driven by commercial interests and capital market pressures, presents theoretical benefits as established advantages. Current histotripsy studies remain predominantly single-center experiences with
limited follow-up. The technology’s purported immunologic effects remain entirely theoretical, yet marketing
materials present these claims with inappropriate certainty. Patients seek "non-invasive" treatments based on promotional materials overstating capabilities while minimising limitations. This marketing-first approach raises
ethical concerns about informed consent and resource allocation.”
@drugmonkeyblog Been tracking this data for nci. Majority of recent ones are single year awards. Is there any way of parsing what payline and council dates are being funded?
@drugmonkeyblog I read these with great (self interest). I was tracking some of this for NCI. It appears many multi year awards went to ECI. Based on numbers, there’s should be considerable unspent funds remaining with 6 weeks in the FY.
@BladderCancerUS I did go through the criteria. It did not seem my case was a good fit, I wanted to know if an exception could be made. An email to the contact on the site did not elicit any useful guidance. Ergo the public post on Twitter - which advised me to go read the rfa.
@Uber_India wanted to share feedback on a recent trip but the app is restricted on options. Driver showed up just short of the spot, changed status to arrived but kept playing tag when we tried getting into the car. Uber automatically rebooked another taxi.
Driver then stops for pick up and asks me to cancel the other ride as he can take me to destination. When I boarded asked me to pay cash for the original amount. As uber only allows feedback for completed rides, there’s no way of providing feedback on this person with app. #scam